Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 306, Issue 2, 2014, Pages

  Kang, Justin J ^a   Shu, Liming ^b   Park, James L ^b,c   Shayman, James A ^b   Bodary, Peter F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c MAHLE Engine Components USA Inc   (United States)

Author keywords

Fabry disease; Glycosphingolipids; Myograph; Reactive nitrogen species; Renal failure

Indexed keywords

3 NITROTYROSINE; ALPHA GALACTOSIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH MOBILITY GROUP B3 PROTEIN; HOMODIMER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL REACTIVITY; CHROMATOGRAPHY; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; FABRY DISEASE; MESENTERIC ARTERY; MICROVASCULATURE; MOUSE; MURINE MODEL; NONHUMAN; PHENOTYPE; PHOSPHORYLATION; PRIORITY JOURNAL; VASCULAR DISEASE; VASODILATATION; WILD TYPE;

FABRY DISEASE; GLYCOSPHINGOLIPIDS; MYOGRAPH; REACTIVE NITROGEN SPECIES; RENAL FAILURE;

ACETYLCHOLINE; AGING; ALPHA-GALACTOSIDASE; ANIMALS; BLOTTING, WESTERN; CAPILLARIES; FABRY DISEASE; LIPID METABOLISM; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE III; NITROPRUSSIDE; PHENOTYPE; PHOSPHORYLATION; REACTIVE NITROGEN SPECIES; SPLANCHNIC CIRCULATION; TRIHEXOSYLCERAMIDES;

EID: 84892610776     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00185.2013     Document Type: Article

References (27)

1. Atochin DN, Huang PL. Endothelial nitric oxide synthase transgenic models of endothelial dysfunction. Pflügers Arch 460: 965-974, 2010.
2. Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, Gu S, Shayman JA, Eitzman DT. α-Galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111: 629-632, 2005.
3. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramide trihexosidase deficiency. N Engl J Med 276: 1163-1167, 1967.
4. Brandes RP, Schmitz-Winnenthal FH, Feletou M, Godecke A, Huang PL, Vanhoutte PM, Fleming I, Busse R. An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice. Proc Natl Acad Sci USA 97: 9747-9752, 2000.
5. Eitzman DT, Bodary PF, Shen Y, Khairallah CG, Wild SR, Abe A, Shaffer-Hartman J, Shayman JA. Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol 14: 298-302, 2003.
6. Eng CM, Desnick RJ. Molecular basis of Fabry disease: mutations and polymorphisms in the human α-galactosidase A gene. Hum Mutat 3: 103-111, 1994.
7. Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M. Fabry disease: baseline medical characteristics of a cohort of 1,765 males and females in the Fabry Registry. J Inherit Metab Dis 30: 184-192, 2007.
8. 2+/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 88: E68-E75, 2001.
9. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113: 1708-1714, 2006.
10. + channels of small and intermediate conductance control eNOS activation through NAD(P)H oxidase. Free Radic Biol Med 52: 860-870, 2012.
11. Harris MB, Ju H, Venema VJ, Liang H, Zou R, Michell BJ, Chen ZP, Kemp BE, Venema RC. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem 276: 16587-16591, 2001.
12. Kint JA. Fabry's disease: α-galactosidase deficiency. Science 167: 1268-1269, 1970.
13. Lin MI, Fulton D, Babbitt R, Fleming I, Busse R, Pritchard KA Jr, Sessa WC. Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. J Biol Chem 278: 44719-44726, 2003.
14. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38: 769-775, 2001.
15. Michell BJ, Chen Z, Tiganis T, Stapleton D, Katsis F, Power DA, Sim AT, Kemp BE. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 276: 17625-17628, 2001.
16. Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, Sugimoto Y, Pastan I, Gottesman MM, Brady RO, Kulkarni AB. α-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 94: 2540-2544, 1997.
17. Park JL, Whitesall SE, D'Alecy LG, Shu L, Shayman JA. Vascular dysfunction in the α-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin Exp Pharmacol Physiol 35: 1156-1163, 2008.
18. Park S, Kim JA, Joo KY, Choi S, Choi EN, Shin JA, Han KH, Jung SC, Suh SH. Globotriaosylceramide leads to KCa3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease. Cardiovasc Res 89: 290-299, 2011.
19. Rafikov R, Fonseca FV, Kumar S, Pardo D, Darragh C, Elms S, Fulton D, Black SM. eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity. J Endocrinol 210: 271-284, 2011.
20. Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95: 86-92, 2006.
21. Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, Takayanagi T, Nagao T, Egashira K, Fujishima M, Takeshita A. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 28: 703-711, 1996.
22. Shu L, Park JL, Byun J, Pennathur S, Kollmeyer J, Shayman JA. Decreased nitric oxide bioavailability in a mouse model of Fabry disease. J Am Soc Nephrol 20: 1975-1985, 2009.
23. Shu L, Shayman JA. Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of α-galactosidase A null mice. J Biol Chem 282: 20960-20967, 2007.
24. Singh U, Devaraj S, Vasquez-Vivar J, Jialal I. C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol 43: 780-791, 2007.
25. Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, Bruhl K, Gal A, Bunge S, Beck M. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24: 715-724, 2001.
26. Yang YM, Huang A, Kaley G, Sun D. eNOS uncoupling and endothelial dysfunction in aged vessels. Am J Physiol Heart Circ Physiol 297: H1829-H1836, 2009.
27. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 109: 817-826, 2002.